A prospective study of direct-acting antiviral effectiveness and relapse risk in HCV cryoglobulinemic vasculitis by the Italian PITER cohort.
Loreta Anesti KondiliMonica MontiMaria Giovanna QuarantaLaura GragnaniValentina PanettaGiuseppina BrancaccioCesare MazzaroMarcello PersicoMario MasaroneGentile IvanPietro AndreoneSalvatore MadoniaElisa BiliottiRoberto FilomiaMassimo PuotiAnna Ludovica FracanzaniDiletta LaccabueDonatella IeluzziCarmine CoppolaMaria Grazia RumiAntonio BenedettiGabriella VerucchiBarbara CocoLiliana Lc ChemelloAndrea IannoneAlessia CiancioFrancesco Paolo RussoFrancesco BarbaroFilomena MoriscoLuchino ChessaMarco MassariPierluigi BlancAnna Linda ZignegoPublished in: Hepatology (Baltimore, Md.) (2022)
In patients with CV, HCV eradication may not correspond to a persistent clinical improvement, and clinical response may fluctuate. This implies an attentive approach to post-SVR evaluation through prognostic factors and tailored treatment.